CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.
UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.
Source: finance.yahoo.com
Related posts:
Expect a major market sell-off in first half of year: Strategist
Buy These 2 Stocks Before They Jump Over 80%, Say Analysts
Bankman-Fried’s Evasive Answers Again Irk Judge
Gen Z is embracing ‘lazy girl jobs’ in a rebuke of millennials’ ‘girlboss’ and ‘lean in’ manias
Chinese EV Maker Nio to Cut 10% of Staff Positions and May Spin Off Businesses